Bdallc.com

ASIA IS A BUSINESS IMPERATIVE… NOW MORE THAN EVER A bimonthly newsletter of developments in the pharmaceutical, hospital and medical device markets Beijing Wanhui Pharmaceutical (Wanhui), a sub- sidiary of China’s Beijing Medicines Group Cor- poration (BMGC), has acquired Beijing Pharma- ceutical Plant. After the merger, Wanhui will re- place Beijing Pharmaceutical Plant as the largest share- holder of Beijing Double Crane Pharmaceutical Co Ltd. BMGC produces a range of pharmaceutical products, including traditional Chinese medicine FOCUS: Japanese pharmaceutical industry . 5 (“TCM”), chemical formulations and nutritional Kobayashi Pharmaceutical of Japan, a manufac- turer and marketer for OTC drugs, deodorants, oral and other hygiene products, will invest ¥250m We hope that you find the Asian Health Newsletter (US$2.3m) to expand its facilities in Shanghai, China.
informative. In this issue we look at the The company also plans to expand its facilities in Eu- pharmaceutical sector in Japan and profile three companies that are responding well to the changing competitive environment. In India we see several Shanghai Fuxing Industrial Co Ltd of China will new online ventures targeting the B2B segment for acquire a 24% stake in Shanghai Leiyunshang pharmaceutical exchange and distribution.
Pharmaceutical North Area Co Ltd (SLPNA) for RMB25m (US$3m). Leiyunshang Pharmaceutical op- BDA is a corporate finance advisory firm which helps erates 60 pharmaceutical chain stores and also oper- multinational clients to identify and to execute ates the Leiyunshang Traditional Chinese Medi- acquisitions and JVs in Asia. We focus on the cine Factory. It achieved 1999 revenues of healthcare sector and are well placed to help Western RMB484m (US$58m). After the acquisition, Shang- companies structure mutually beneficial transactions hai Fuxing will become the second largest shareholder If you think that BDA’s services may be useful to Shanghai Industrial United Pharmaceutical Co you, please contact me at [email protected].
Ltd, a subsidiary of Shanghai Industrial United Holdings Co Ltd, has acquired a 42% stake in Changzhou Pharmaceutical Co Ltd to become its Shanghai Zhongxi Pharmaceutical Co Ltd of Davabazaar Online Ltd of India has launched China will sell its 50% stake in Shanghai Zhongxi davabazaar.com, India’s first B2B portal to distrib- Xinshengli Biology Engineering Co Ltd, a nucleic ute generic drugs. The main objective of the portal is acid healthcare product manufacturer, to Shenzhen to add value to the marketing and distribution efforts Zhongke Chuagye (Group) Co Ltd. Zhongxi Phar- of pharmaceutical companies by helping them to maceutical holds a 90% equity stake in Zhongxi reach their buyers directly. (September 20, 2000) Dr. Reddy’s Laboratories Ltd (DRL), one of the Wuhan Pharmaceutical Technological and In- leading pharmaceutical companies in India, has ac- dustrial Park has started construction of the first quired three brands, Dinoripe Gel, Deviprost and PG pharmaceutical industrial center in Wuhan, Hubei Tab, in the segments of women’s health from Dai- Province. Wuhan Zhongbai Group and Zhonglian Ichi Karkaria Ltd, a Mumbai based specialty chemi- Pharma, who together own 70% of the US$18m cals company. Dai-Ichi Karkaria produces bulk phar- entity, are the two major investors. Wuhan State maceutical actives, pharmaceutical formulations as Assets Group and Miaoshan Development Zone, well as pharmaceutical intermediates and chemical own the remaining 30%. The park will produce bio- products. DRL has also entered an exclusive manu- chemical drugs, chemical drugs and natural medicinal facturing agreement with Dai-Ichi Karkaria, for the drugs once it becomes operational in 2001. The own- latter to continue manufacturing the three brands.
ers predict that the park will generate revenues of US$120m within 5 years. (September 8, 2000) Ferring Pharmaceuticals Inc of the US will set up Xi’an Lijun Pharmaceutical Co Ltd has been es- a research and development facility for peptide-based tablished on the site of the former Xi’an Pharma- drugs in India. The company established its Indian ceutical Factory. The US$60m company will pro- subsidiary in 1998 an set up manufacturing facilities duce bulk drugs, medicine preparations and food pre- recently. It recorded 1999 revenues of Rup100m servatives. It claims a comprehensive distribution net- work containing eight sales companies and 180 re- gional sales agents. It recorded 1999 revenues of Glaxo SmithKline plc of the UK will merge its In- US$82m and expects revenues to exceed US$120m dian subsidiaries following the merger of the parent companies, Glaxo Wellcome plc of the UK and SmithKline Beecham of the US. The four subsid- iaries are Glaxo India Ltd, Burroughs Wellcome, SmithKline Beecham Consumer Health Care and SmithKline Beecham Pharmaceuticals. (Septem- Medybiz.com of India, an Internet and telephone Bayer India, the Indian subsidiary of Bayer AG of health service company, is to set up a LDSP network, Germany, has received approval to set up a wholly which will enable trading in medicines, equipment and owned subsidiary, Bayer Pharmaceuticals, in India.
hospital-consumables. The company has also formed Bayer India will continue to manufacture pharma- an alliance with six pathological laboratories, 60 doc- ceuticals at its unit and supply to Bayer Pharmaceuti- tors and outsourced customer relations company cals under a toll manufacturing agreement. Bayer Mobilink for its call center facilities. (September 23, Group will invest Rup70m (US$1.5m) in Bayer India and transfer marketing activities to Bayer Pharma- ceuticals. More than 300 employees will be trans- PharmaChem Network Pvt Ltd (PNPL) of India ferred from Bayer India to the new subsidiary. Rev- has launched a portal, www.myPharmaChem.com that enues in the pharmaceutical segment accounted for allows access to pharmaceutical industry and real time 4% of Bayer group’s total revenues in India, and 12% news. The portal is a membership-based online work- of Bayer India’s revenues. (September 8, 2000) place that contains information about Indian phar- maceutical manufacturers, dealers, exporters and po- Reddy’s Laboratories Ltd, Lupin Laboratories tential buyers in the industry. (September 11, 2000) Ltd, Nicholas Piramal India Ltd, Ranbaxy Labo- ratories Ltd, Sun Pharmaceutical Industries Ltd, Ranbaxy Laboratories Ltd of India has acquired Wockhardt Ltd and Zydus Cadila Ltd. (Septem- the generics business of Bayer AG of Germany. The acquired products, under the brand name Basics, will be incorporated into a newly set up 100% owned sub- sidiary, Basics GmbH, by Ranbaxy. Ranbaxy plans to add new products of its own to the portfolio and expects its revenues in Germany to be US$5m. The company will manufacture the products in its facili- ties in India and Ireland and through licensed compa- nies in Germany. Ranbaxy also plans to acquire small AstraZeneca Plc of the UK plans to merge its Japa- to medium sized companies in France and Spain in a nese pharmaceutical subsidiary, AstraZeneca KK, and move to double its revenues in Europe by 2004. (Sep- its 60:40 JV with Japan’s Sumitomo Chemical, AstraZeneca and Sumitomo, called AstraZeneca KK, Shantha Biotechnics Pvt Ltd of India has invested will produce a variety of products, including cardio- Rup45m (US$1m) in ABL Biotech of India. Shantha vascular and oncology drugs, and is expected to have expects to develop marine biotechnology, beta caro- annual revenues of ¥100bn (US$925m). AstraZeneca tene and blood-clotting agents from seaweed and other also plans to have 20 of its new products approved marine materials through the acquisition. Shantha and marketed in Japan in the next five years. (Sep- has also acquired a 51% stake in East West Labora- tories of the US. Shantha recorded revenues of Rup330m (US$7.2m) in 1999 and is expected to in- Fujisawa Pharmaceutical Co Ltd of Japan will crease revenues to Rup600m (US$13m) by March merge its three domestic subsidiaries, Izumisha Co Ltd, Shinryoshinsha Co Ltd and Hitomi Art Co Ltd, into one unit in October 2000. The unit is ex- Strides Arcolab Ltd of India and Bombay Drugs pected to have revenues of approximately ¥500m and Pharmas Ltd of India have agreed to merge.
Strides Arcolab is a contract research organization and toll manufacturer for leading pharmaceutical com- Kao of Japan and Novartis Consumer Health of panies. It manufactures pharmaceuticals and nutri- Switzerland will set up a JV to develop and market tional supplement range from all dosage forms to OTC drugs, including drugs for the treatment of back therapeutic categories. The company recorded 1999 and muscle pain and fatigue, in Japan. Novartis will revenues of Rup1.7bn (US$38m). Bombay Drugs contribute its expertise in the conversion of prescrip- and Pharmas is a manufacturer and exporter of phar- tion drugs to OTC to the JV, and Kao will conduct maceutical intermediates and specialty and perfor- sales through its extensive network of drug chain mance chemicals. The merger is subject to approval by the High Court of Mumbai. (September 20, 2000) Kuraya Sanseido of Japan will acquire a 51% eq- Kohinoorpharma.com, an online pharmaceutical uity stake in Chiyaku, a drug wholesaler in Japan.
exchange, was jointly established by nine leading In- This will be the company’s sixth wholesale subsidiary.
dian pharmaceutical firms. The venture will market Kuraya Sanseido expects to increase its revenues to products and services of its founding members, set ¥1,080bn (US$10bn) after the integration. (Septem- up a pharmaceutical exchange and develop a domes- tic web-based supply chain distribution network. The founding Indian pharmaceutical companies include: Mitsubishi Corp of Japan has acquired a 4% equity Alembic Chemical Works Ltd, Cipla Ltd, Dr stake in Iomai Corp, a US start-up, for US$2m, through its CZ Venture Operations Inc unit. Iomai mainly fat-soluble types, while Takeda is one the world’s developed and patented a vaccine seal that allows leading maker of water-soluble vitamins, with rev- vaccines to permeate the body through the skin. (Sep- enues of US$210m. The merger has been approved by US Antitrust Agencies and is subject to approval from European and other competition agencies. (Sep- Pherin Pharmaceuticals Inc of the US has signed a research and option agreement with Japan’s Taisho Pharmaceutical Co Ltd to discover, develop and Toho Pharmaceutical of Japan will acquire the commercialize Pherin’s proprietary vomeropherin business rights of the drug wholesale division of technology in three human therapeutic areas. Taisho Oshima Yakuhin of Japan. Oshima Yakuhin had will provide initial funding of US$9m over a three- revenues of ¥1.4bn (US$13m) in 1999. (September year period. Taisho is the leading OTC pharmaceuti- cal company in Japan. (September 12, 2000) Quintiles Transnational Corp (Quintiles) of the US has opened a Quintiles Japan Pharma Centre in Scotland. The center provides information about the European markets to Japanese pharmaceutical companies, especially medium-sized and emerging firms who wish to enter the European markets. The Green Cross of Korea has sold its 80% equity stake, first Quintiles Japan Pharma Center was opened in worth W10bn (US$9m) in Korea’s Greenmate Corp to Fresenius Kabi of Germany. Under the agree- ment signed by Greenmate and Fresenius, Greenmate Sankyo Co Ltd of Japan will acquire Pfizer’s stake will operate under the name, Fresenius Kabi Green in their 50:50 JV, Sankyo Parke Davis, through Cross. It will serve as the basis for Fresenius Kabi to Sankyo’s US subsidiary, Sankyo Pharma Inc, for an introduce its infusion and nutrition therapy products undisclosed sum. Sankyo produces pharmaceuticals, in the Korean market. Greenmate is one of the lead- medical devices and diagnostics, as well as agrochemi- ing providers of parenteral nutrition in Korea, with cals, food, cosmetics, veterinary drugs and fine chemi- 1999 revenues of W10.8bn (US$16.2m). (Septem- Shiseido Co Ltd of Japan has refocused its pharma- Santen Pharmaceutical of Japan has established a ceutical division on four brands of dermatological subsidiary, Santen Korea Pharmaceutical Co Ltd products. Shiseido’s pharmaceutical division reported in Korea, in the hope of expanding into the Korean revenues of ¥5bn (US$46.5m) in 2000 and expects to increase the revenue to ¥10bn (US$93m) in 2002.
Takeda Chemical Industries Ltd of Japan and BASF AG of Germany have agreed to merge their vitamin businesses. Under the agreement, Takeda will transfer related assets to BASF. The two companies will form a JV in Japan for the sale and distribution Unza Holdings Bhd of Malaysia has acquired of a joint range of bulk vitamins. Outside of Japan, BASF will assume sole responsibility worldwide for Formapac Sdn Bhd, two personal care product com- the combined vitamin product range. BASF is the panies in Malaysia for a total of RM48m (US$12.6m).
world’s second largest manufacturer of vitamins, Gervas Corp distributes and sells mainly haircare, skincare, babycare and bodycare products, while Formapac is a contract manufacturer of personal care products. With the acquisitions, Unza will increase its market share in the personal care and household prod- Daiichi Pharmaceutical (Thailand) is now a 100% ucts sector in Malaysia, and add ten additional estab- subsidiary of Daiichi Pharmaceutical of Japan, lished trademarks to its product portfolio. (August following the parent company’s acquisition of the 51% stake owned by Watana Inter-Trade Ltd and the 15.7% stake owned by Kanematsu. (October 5, 2000) Chiron Corp of the US has formed a JV, S*Bio, with PharmBio Growth Fund (PGF) of Singapore to develop pharmaceuticals based on small molecules.
Chiron will invest US$8m, a 20% contribution to the Japan’s record long life expectancies and low birth project, while the Singapore Government will invest rates have created one of the fastest graying popula- the remaining 80%. As part of the agreement, Sin- tions in the world. This demographic trend is ex- gapore will receive rights for genetic expression and pected to continue for the foreseeable future, espe- combinatory chemistry processes from Chiron. PGF cially in the continued absence of immigration. A full is run by an investment department of the Singapore quarter of the population is expected to be over the Authority for Economic Development. (Septem- age of 65 by the year 2020 if current birth rate is Dairy Farm International, the Jardine Matheson Pharmaceuticals manufacturers in Japan have long Group subsidiary which owns Guardian Pharma- benefited from government-controlled prescription cies, has bought a 51% stake in Apex Pharmacy drug prices, non-tariff barriers against foreign com- International. Dairy Farm acquired the stake from petition and a national health policy that encouraged health professionals to dispense prescriptions. The US$11.5m. The enlarged chain now accounts for equity market has long recognized the pharmaceuti- over 50% of the market in Singapore. Dairy Farm cal industry’s capacity to grow even during much of will acquire the leases, assets and staff of all 23 Apex the economic contraction of the 1990s. The TOPIX stores. These will be rebranded under the Guardian pharmaceuticals sub-index was one of only two sec- name. Pharmaceutical products supplier Grafton tors that consistently outperformed the broader mar- Pharmasia, Apex’s sister-company under UE, will be ket during the past decade. A Bank of Japan study in granted preferred supplier status by the enlarged chain.
1996 found that the industry enjoyed an average net profit margin 6.5%, which substantially exceeds the sub-1% margins common in the automobile and elec- The government’s accommodative pricing policy and To submit stories to future editions of the Asian Health absence of foreign competition have resulted in low Newsletter please contact Kathleen Ng on (65) 533-8506 R&D expenditure and a lackluster pipeline of new drugs. The absence of high R&D budgets and few blockbuster drugs partially explains why M&A Ownership Structure: Nippon Life 9.3%, Daiichi activity has been relatively quiet in Japan. Size does matter in the West, where development and market- ing budgets can easily top U$500m to bring a drug to Key Financials: Takeda’s revenues increased faster market. Japanese pharmaceutical companies have than any of its peers, at 9.3% YoY for FY1999. Phar- historically specialized in licensing products developed maceuticals and Healthcare Products, in particular, abroad and distributing them in the domestic market.
saw robust growth, rising over 13.8% to ¥597.6bn (U$5.6bn). Q1 00 (ending June 2000) results were This operating environment of the industry may be equally impressive, with sales rising 14.1% on the back coming to an end. In response to public criticism and of strong demand for its mainstay products, Basen rising healthcare costs associated with an aging popu- (anti-diabetic) and Blopress (anti-hypertensive).
lation, the government introduced biennial price re- ductions of between 6%-10%. Although this is not Points to Consider: The company recently an- the first time the industry had to cope with govern- nounced plans to withdraw from the bulk vitamin ment mandated price cuts, the price cut comes at a business. It will transfer the business to the new 33% time when foreign competitors are increasing their held JV formed with BASF in July 2000. This an- presence in the Japanese market by taking share away nouncement should complete the company’s restruc- turing plans announced two years ago, which has en- compassed withdrawals from cosmetics, veterinary The key steps to survival in the industry will be R&D, medicines, and other unprofitable businesses. Takeda partnerships with foreign manufacturers and cultivat- is one of the leaders in genome drug research, and ing viable export markets. The market leader , Takeda has a first class development pipeline.
Chemicals, has been particularly active on this end, and is one of a handful of firms to have a deep new product pipeline of drugs that will be competitive in the global markets. We have profiled a select group of Japanese pharmaceutical companies that are now Business Summary: Kyorin Pharmaceutical was enacting large-scale reforms and/or have developed established in 1940 but became a public corporation strong new product pipelines, which we believe puts only in 1999. The company focuses on antibiotics, them in a relatively strong position as the Japanese circulatory and respiratory drugs and chemotherapeu- pharmaceutical industry begins to restructure and face Senior Management: Minoru Ogihara, Chairman; Ikuo Ogiwara, President; Hiroshi Uchida, Senior Business Summary: Takeda is Japan’s largest phar- Ownership Structure: Apricot Co is the major share- maceuticals manufacturer. The company’s product holder with 27.0% of the company. Closely held concentration is in ethical drugs (64% of revenues), shares amount to over 50% of the equity capital.
but it is also involved in healthcare products, vita- mins, agrochemicals and environmental materials Key Financials: Kyorin reported FY1999 revenues manufacturing. The company’s particular strengths (ending March, 2000) of ¥46.9bn (U$438m), and lie in cancer research, ulcer agents and diabetic drugs.
achieved gross margins of 70.6%, one of the highest in the industry. The company spent ¥5.58bn Senior Management: Masahiko Fujino, Chairman; (U$52.1m) or 12% of revenues on R&D in 1999, Kunio Takeda, President; Hideyuki Nagasawa, Senior which is approximately four times the industry av- Points to Consider: Kyorin’s strengths are in the Ownership Structure: Hokuriku Bank 4.9%, Sakura development of antibacterial agents to treat respira- tory diseases and antibiotics. The company’s newest antibiotic is TEQUIN (gatifloxacin), a quinolone-based Key Financials: FY1999 revenues were ¥46.8bn antibiotic that has been proven effective against com- (U$439m), an increase of 3.8% from the previous munity acquired respiratory tract infections. The new year. Net profits fell to -¥4.65bn (-U$43.5m) due to drug is marketed in conjunction with Bristol-Myers an extraordinary expense of ¥9.7bn (U$90.7m) in- curred from costs associated with its early retirement Points to Consider: The company’s restructuring program over the last six years has reduced headcount Business Summary: Toyama Chemical Co is a com- by 24% and streamlined the product line to focus on prehensive pharmaceutical manufacturer specializing three areas: cerebral function drugs (Alzheimer’s re- in antibiotics and oncology drugs, which collectively search), anti-inflammatory agents (rheumatoid arthri- accounted for over 52% of the FY1999 revenues.
tis) and anti-biotics. Toyama has formed various stra- tegic alliances with domestic and US companies to Senior Management: Katsuhiko Nakano, President market its neuroprotective pharmaceuticals under & CEO; Takeo Abe, Senior Managing Director; Hideo Business Development Asia is a corporate finance advisory firm which assists US companies in expanding their businesses in Asia. BDA helps clients to find local business and has senior advisors in Bangkok, Jakarta, Kuala Lumpur, Manila, Seoul, Shanghai, Taipei and Tokyo. For further information on BDA’s services or on any of the articles in this newsletter, please contact Charles Maynard in New York, Euan Rellie in London, Andrew Huntley in Singapore, Frank Zhang in Shanghai or Kumiko

Source: http://www.bdallc.com/wp-content/uploads/2012/08/211.pdf